Novo Nordisk CFO outlines ‘ultimate defense’ against stock downgrades and lawsuits to retain weight-loss crown

Novo Nordisk is facing significant headwinds, with its Q3 2025 outlook projecting a sharp deceleration in sales and operating profit growth to 8-11% and 4-7% respectively, down substantially from prior year's figures, contributing to a more than 50% year-to-date share price decline. This weakening outlook is primarily driven by impending patent expirations for its blockbuster GLP-1 drugs like Ozempic and Wegovy, alongside intensifying competition from rivals such as Eli Lilly. In response, Novo Nordisk is prioritizing innovation, planning to launch a Wegovy pill, CagriSema, and amycretin as its 'silver bullet' strategy to defend market share, particularly as critical U.S. patents expire in the early 2030s, while also navigating various legal challenges including anticompetition lawsuits and product liability claims.

Analysis

Novo Nordisk (NVO) reported a significant deceleration in its Q3 2025 outlook, projecting full-year sales growth of 8-11% and operating profit growth of 4-7% at constant exchange rates. This marks a sharp decline from the prior year's 24% sales and 22% operating profit growth, contributing to NVO's share price falling over 50% year-to-date. The weakening outlook is primarily attributed to impending patent expirations for its blockbuster GLP-1 drugs, with some expiring as early as next year, and intensifying competition from rivals like Eli Lilly (LLY).

In response, Novo Nordisk is prioritizing innovation as its "silver bullet" strategy to defend market share. The company plans to launch a Wegovy pill in the U.S. next year, alongside new medications like CagriSema (weekly obesity drug) and amycretin (daily oral diabetes drug). These new products are crucial for mitigating the impact of patent cliffs, especially as key U.S. patents, representing 50% of group sales, are set to expire in the early 2030s.

Concurrently, NVO is navigating multiple legal challenges, including an anticompetition lawsuit from Pfizer (PFE) regarding its Metsera (MTSR) acquisition and claims of product side effects. While the CFO acknowledges a "low single-digit negative impact" from patent expirations in certain markets next year, he expresses confidence in the company's legal capabilities and risk management. These legal battles, however, could prove costly and lengthy, potentially impacting the bottom line.

Key Decisions for Investors

• Monitor the successful commercialization and market penetration of Novo Nordisk's next-generation GLP-1 pipeline, including the Wegovy pill, CagriSema, and amycretin, as these are crucial for offsetting impending patent expirations and competitive pressures.
• Assess the financial impact and resolution timelines of Novo Nordisk's various legal challenges, particularly the anticompetition lawsuit and product liability claims, which could introduce significant unforeseen costs.
• Evaluate the evolving competitive landscape, specifically Eli Lilly's progress with Mounjaro and its pill form, to understand potential market share erosion and pricing dynamics for Novo Nordisk's core products.